Industry Pipeline - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Pipeline
Pre-Interphex 2010 Product Releases.

Pharmaceutical Technology
Volume 34, Issue 3, pp. 83-87

LABORATORY EQUIPMENT & SUPPLIES



Laboratory blenders
MaxiBlend and MiniBlend laboratory blenders are available in sizes from 0.5 to 16 qt. The units are made of 316-L stainless steel and supplied with V-shells, bins, or double cones. The units feature a tabletop design and include programmable logic controls and safety-interlocked guards. GlobePharma, New Brunswick, NJ http://www.globepharma.com/ tel. 732.819.0381



Weighing terminal
The IND560 weighing terminal from Mettler Toledo allows users to choose between conventional strain gauge or high-precision, electromagnetic-force restoration weighing technologies. The unit is compatible with direct program logic controllers such as Profibus and DeviceNet, as well as Ethernet communication interfaces and internal and external digital I/O control. An IP65-rated panel and IP69k heavy-washdown mounting are available options. Atlantic Scale Co., Nutley, NJ http://www.atlanticscale.com/ tel. 973.661.7090



Total-organic-carbon analyzer
The Anatel TOC600 on-line total-organic-carbon analyzer is designed for pharmaceutical water measurement. Its patented stop-flow oxidation technology provides complete oxidation of an aliquot of water and fully complies with USP Chapter <643> and EP 2.2.44. The Anatel TOC600 unit's wide dynamic range allows for monitoring an array of water-system applications. Hach Ultra Analytics, Grants Pass, OR http://www.hachultra.com/ tel. 541.472.6500


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here